Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027526 | 0.85 | AHR (0.46) | AHRSMN1; SMN2L3MBTL1KCNN4KDM4E | |
| SCHEMBL11396996 | 0.84 | L3MBTL1 (0.47) | AHRSMN1; SMN2L3MBTL1KDM4ENPC1 | |
| SCHEMBL11001068 | 0.83 | SMN1; SMN2 (0.50) | AHRSMN1; SMN2L3MBTL1KCNN4KDM4E | |
| SCHEMBL1171499 | 0.82 | POLB (0.47) | AHRSMN1; SMN2L3MBTL1KDM4EGAA | |
| SCHEMBL12746102 | 0.82 | L3MBTL1 (0.52) | AHRSMN1; SMN2L3MBTL1KDM4ENPC1 | |
| SCHEMBL504847 | 0.81 | PLCG1 (0.51) | AHRSMN1; SMN2L3MBTL1KCNN4KDM4E | |
| SCHEMBL28403522 | 0.81 | SMN1; SMN2 (0.47) | AHRSMN1; SMN2L3MBTL1KCNN4KDM4E | |
| SCHEMBL2465434 | 0.80 | SMN1; SMN2 (0.50) | AHRSMN1; SMN2L3MBTL1KDM4ENPC1 | |
| SCHEMBL9978324 | 0.79 | SMN1; SMN2 (0.46) | AHRSMN1; SMN2L3MBTL1KCNN4KDM4E | |
| SCHEMBL10334728 | 0.79 | SMN1; SMN2 (0.46) | AHRSMN1; SMN2L3MBTL1KCNN4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3541802-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093576-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | AHR 220/4885SMN1; SMN2 4701/4885L3MBTL1 4741/4885 |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, APLNR | AHR 220/4885SMN1; SMN2 4701/4885L3MBTL1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.